JZB 61
Alternative Names: JZB-61Latest Information Update: 09 Jan 2023
At a glance
- Originator Shanghai Jingze Biotechnology
- Class Infertility therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Oligospermia
Most Recent Events
- 09 Jan 2023 Clinical trials in Oligospermia in China (Parenteral) (Shanghai Jingze Biotechnology pipeline; January 2023)
- 13 Sep 2022 JZB 61 is available for licensing as of 23 Aug 2022. https://jingzepharma.com/en/coop.html
- 22 Aug 2022 Preclinical trials in Oligospermia in China (Parenteral) (Shanghai Jingze Biotechnology pipeline, August 2022)